Ehsan Rahimy, MD addresses barriers like step edits with bevacizumab and biosimilars in nAMD, emphasizing the impact of insurance-guided choices on treatment outcomes and advocating for a personalized approach.
Back
Addressing Treatment Dilemmas in Neovascular AMD and DME
An expert retina specialist discusses typical challenging scenarios, including step edits and inadequate responses to anti-VEGF treatment, frequently encountered in managing patients with neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME), and outlines effective strategies to address these issues.
Addressing Treatment Dilemmas in Neovascular AMD and DME
Episodes
All
All
Retina expert shares his strategy for managing a patient recently diagnosed with nAMD who started on bevacizumab, discussing criteria for transitioning to more efficacious therapy.
Ehsan Rahimy, MD, discusses challenges in managing longstanding nAMD patients rotating through anti-VEGF treatments, highlighting the promise of newer therapies like aflibercept 8mg and faricimab.
An expert retina specialist discusses challenges faced by DME patients showing suboptimal response to standard anti-VEGF treatment, emphasizing the need to reduce injection burden while preventing vision loss.
Ehsan Rahimy, MD, outlines strategies for managing cases of high-risk PDR and DME, exploring new therapies and synergistic combinations with anti-VEGF and steroids for longer-lasting responses.
Advertisement
Advertisement
Trending on HCPLive
1
Kidney Compass: VISIONARY 2-Year eGFR Data in IgA Nephropathy
2
Q&A: Bimekizumab 2-Year Efficacy by HS Disease Duration, With Raj Chovatiya, MD, PhD
3
Bimekizumab Data Support Case for Earlier Intervention in HS
4
One Year of Brensocatib: How Bronchiectasis Care Has Changed
5